AR025110A1 - Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina - Google Patents

Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina

Info

Publication number
AR025110A1
AR025110A1 ARP000104189A ARP000104189A AR025110A1 AR 025110 A1 AR025110 A1 AR 025110A1 AR P000104189 A ARP000104189 A AR P000104189A AR P000104189 A ARP000104189 A AR P000104189A AR 025110 A1 AR025110 A1 AR 025110A1
Authority
AR
Argentina
Prior art keywords
dose
compositions
methods
treat
low dose
Prior art date
Application number
ARP000104189A
Other languages
English (en)
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Publication of AR025110A1 publication Critical patent/AR025110A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos y composiciones que comprenden una dosis muy baja de ciclobenzaprina o un metabolito de la misma para prevenir y tratar alteraciones del sueno yenfermedades que se manifiestan con una disfuncion del sueno, incluyendo síndrome defibromialgia, síndrome de fatiga cronica, trastornos del sueno, trastornosde dolor psicogénico, o síndromes de dolor cronico, o síntomas de las mismas. La presente se refiere además a métodos y composiciones para tratar alteracionesdel sueno, dolorcronico o fati ga en humanos que sufren de síndrome de fibromialgia, síndrome de fatiga cronica, trastornos del sueno, trastornos de dolorpsicogénico, síndromes de dolor cronico, usando una dosis muy baja de ciclobenzaprina.
ARP000104189A 1999-08-13 2000-08-11 Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina AR025110A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14888199P 1999-08-13 1999-08-13

Publications (1)

Publication Number Publication Date
AR025110A1 true AR025110A1 (es) 2002-11-06

Family

ID=22527835

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104189A AR025110A1 (es) 1999-08-13 2000-08-11 Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina

Country Status (18)

Country Link
US (3) US6395788B1 (es)
EP (1) EP1202722B1 (es)
JP (1) JP2003506484A (es)
AR (1) AR025110A1 (es)
AT (1) ATE299369T1 (es)
AU (1) AU6635400A (es)
BR (1) BR0013017A (es)
CA (1) CA2380432A1 (es)
DE (1) DE60021266T2 (es)
ES (2) ES2245944T3 (es)
GB (1) GB2368522A (es)
HK (2) HK1047691B (es)
IL (1) IL147777A0 (es)
MX (1) MXPA02001569A (es)
NZ (1) NZ516749A (es)
PT (1) PT1202722E (es)
WO (1) WO2001012175A1 (es)
ZA (2) ZA200200619B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537245A (ja) * 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト ５−ｈｔ３レセプターアンタゴニストの使用
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
GB0128674D0 (en) * 2001-11-30 2002-01-23 Boots Co Plc Treatment of sleep disorders and the like
JP4578083B2 (ja) * 2003-09-30 2010-11-10 小林製薬株式会社 催眠剤組成物
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
JP5302005B2 (ja) 2005-12-01 2013-10-02 オースペックス・ファーマシューティカルズ・インコーポレイテッド セロトニン作動性および／またはノルエピネフリン作動性の活性を有する置換フェネチルアミン
EP1984066B1 (en) * 2006-02-16 2020-05-06 Imthera Medical, Inc. An rfid based system for therapeutic treatment of a patient
US20100179215A1 (en) * 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
CA2680912C (en) 2007-03-15 2017-11-14 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
JP2011500143A (ja) 2007-10-09 2011-01-06 イムセラ・メディカル・インコーポレーテッド 選択的刺激のための装置、システム、及び方法
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
WO2010042404A1 (en) 2008-10-09 2010-04-15 Imthera Medical, Inc. Method of stimulating a hypoglossal nerve for controlling the position of a patient's tongue
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
CA2780096A1 (en) 2009-11-10 2011-05-19 Imthera Medical, Inc. System for stimulating a hypoglossal nerve for controlling the position of a patient's tongue
DK2501234T3 (en) 2009-11-20 2017-12-04 Tonix Pharma Holdings Ltd METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS CONNECTED WITH POSTTRAUMATIC LOAD RESPONSE USING CYCLOBENZAPRINE
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) * 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
US9346742B2 (en) * 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
MX2014015436A (es) 2012-06-15 2015-07-14 Tonix Pharmaceuticals Inc Composiciones y metodos para absorcion transmucosa.
CN105142730B (zh) 2013-03-15 2019-04-16 通尼克斯制药有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
WO2016044796A1 (en) 2014-09-18 2016-03-24 Seth Lederman Eutectic formulations of cyclobenzaprine hydrochloride
CA3069699A1 (en) 2017-07-13 2019-01-17 Tonix Pharmaceuticals Holding Corp. Analogs of cyclobenzaprine and amitryptilene
SG11202004799TA (en) 2017-12-11 2020-06-29 Tonix Pharma Holdings Ltd Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2020039256A1 (en) 2018-08-20 2020-02-27 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
JP2023521167A (ja) * 2020-04-08 2023-05-23 トニックス ファーマシューティカルズ ホールディング コーポレーション 性機能障害のシクロベンザプリン処置
US20240009146A1 (en) 2020-11-20 2024-01-11 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for alcohol use disorder
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1339636A (en) * 1917-02-23 1920-05-11 Tulloch Thomas Gregorie Fluid-tight joint for steam-pipes and the like
GB859187A (en) 1958-11-25 1961-01-18 United States Borax Chem Method for preparing substituted tris amino boranes
CA958643A (en) 1970-07-07 1974-12-03 Frosst (Charles E.) And Co. Pharmaceutical compositions containing cyclobenzaprine
FR2121529A1 (en) * 1971-01-05 1972-08-25 Merck & Co Inc Compsns contg cyclobenzaprine and indomethacin - chlordiazepoxide, phenylbutazone oxyphenbutazone or corticosteroid
WO2001012174A1 (en) * 1999-08-13 2001-02-22 Vela Pharmaceuticals Inc. Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof

Also Published As

Publication number Publication date
HK1047883A1 (zh) 2003-03-14
ES2192156A1 (es) 2003-09-16
BR0013017A (pt) 2002-04-16
US20010046988A1 (en) 2001-11-29
ZA200200619B (en) 2003-04-23
US6395788B1 (en) 2002-05-28
GB2368522A8 (en) 2002-06-13
ZA200200852B (en) 2003-07-30
IL147777A0 (en) 2002-08-14
US6541523B2 (en) 2003-04-01
US20040029869A1 (en) 2004-02-12
ES2192156B1 (es) 2005-02-16
GB0202908D0 (en) 2002-03-27
PT1202722E (pt) 2005-11-30
HK1047691A1 (en) 2003-03-07
EP1202722A1 (en) 2002-05-08
WO2001012175A1 (en) 2001-02-22
ATE299369T1 (de) 2005-07-15
HK1047691B (zh) 2006-05-12
EP1202722B1 (en) 2005-07-13
ES2245944T3 (es) 2006-02-01
NZ516749A (en) 2004-03-26
GB2368522A (en) 2002-05-08
DE60021266D1 (de) 2005-08-18
AU6635400A (en) 2001-03-13
CA2380432A1 (en) 2001-02-22
JP2003506484A (ja) 2003-02-18
MXPA02001569A (es) 2002-07-02
DE60021266T2 (de) 2006-05-24
WO2001012175A8 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
AR025110A1 (es) Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina
AR025111A1 (es) Metodos y composiciones para tratar trastornos de ansiedad generalizada
MX2020009246A (es) Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.
DE602005018763D1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
AR048833A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
CY1116215T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
DK1587506T3 (da) Administration af capsaicinoider
EA200501867A1 (ru) Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
RS52825B (en) PROCEDURES FOR THE TREATMENT OF DISORDERS OR DISEASES RELATED TO HYPERLIPIDEMIA AND HYPERHOLESTEROLEMIA WITH MINIMIZATION OF ADVERSE EFFECTS
NO20074018L (no) Forebyggelse av trombotiske lidelser med aktive vitamin D forbindelser eller mimetika derav
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
BR0313411A (pt) Uso de reboxetina para o tratamento de ondas de calor
MA27538A1 (fr) Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
EA200500427A1 (ru) Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
RU2006108398A (ru) Применение экстрактов из пеларгонии
BR0313665A (pt) Utilização de bupropion para o tratamento da sìndrome das pernas inquietas
Wernicke et al. Treatment of chronic pain with drugs that modulate central nervous system serotonin and norepinephrine
ES2690178A1 (es) Plasma de animal o fracciones del mismo para su utilización en el tratamiento de trastornos de deterioro cognitivo en seres humanos y animales de compañia